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Message from the President 
M any of the most intriguing scientific discoveries raise more questions than they answer. Indeed, reading this issue of Search, one is struck by how major new findings and lines of investigation 
at The Rockefeller University have their roots in puzzles that first arose as a 
result of discoveries made decades ago. 
In 1911, for example, Rockefeller scie1;tist Peyton Rous discovered the 
first virus that could cause cancer. It was only last year, however, that the 
laboratory of John Kuriyan was able to 
visualize the 3-D structure of a protein that, 
when defective, enables the virus to trigger 
tumor growth. The structure now allows 
researchers to ask far more precise 
questions about how the protein works in 
both its normal and cancerous forms. 
In 1952, the British physiologists 
J--Iodgkin and Huxley postulated that nerve 
impulses were generated by the movement 
of sodium and potassium ions through 
specialized filters, or "channels," embedded 
in the surface of nerve cells. Earlier this 
year, in a historic achievement, the labora­
tory of Roderick MacKinnon used X-ray 
crystallography to solve the 3-D structure 
of a potassium ion channel protein. This finding resolves the basis of the 
selectivity of the channel for potassium ions. At the same time, it raises new 
questions about how ion channels generate the ordered electrical impulses 
that underlie our perceptions, movements and thoughts. 
Three other articles in this issue describe critical studies of gene replication, 
genetic control of sleep-wake cycles and the signals that form the nervous 
system during embryogenesis. These discoveries, as in the two examples 
mentioned above, are simultaneously yielding answers to classic scientific 
enigmas and are serving as gateways for fundamental new explorations into 
life and disease processes. 
TORSTEN N. WIESEL, PRESIDENT 
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ince the institution's 
earliest days, investigators 
at The Rockefeller 
l.Jniversity have pushed 
the boundaries of science to expand 
our knowledge of the living world, 
· making seminal contributions in
such areas as neuroscience and
FELLER UNIVERSITY 
immunology and pioneering new 
fields such as cell and molecular 
biology. Today, university researchers 
continue to seek answers to many 
basic questions, from how healthy 
cells turn cancerous to why certain 
cells form one tissue but not another. 
From its inaugural days as The 
Rockefeller Institute for Medical 
Research, the university has grown to 
emcompass more than 80 laboratories, 
headed by some of the world's leading 
scientists. Highlighted here is the 
work of three of them. 
SEARCH •
name: Michael O'Donnell 
• SEARCH
laboratory: DNA Replication 
area of study: Mechanisms of DNA replication in bacteria and humans 
tinkering 
WITH tHE GEARS IN THE 
machinery OF life 
I
n the world of proteins, form follows function, 
as these molecules bend and twist into the varied 
shapes that enable them to perform some of the 
most crucial operations in the living cell. Professor 
Michael O'Donnell, head of the Laboratory of DNA 
Replication and an investigator with the Howard 
Hughes Medical Institute, studies the various proteins 
that direct perhaps the most important function in 
the cells of bacteria and humans-the copying of 
DNA during cell division-to gain new insights into 
the development of abnormal cells and to identify 
molecular targets for halting diseases such as cancer. 
Before any cell divides, it must accurately copy its 
DNA and the genetic information carried within it, 
giving each new cell a complete set of instructions on 
how to live and function. "The elegantly simple 
structure of DNA initially suggested that the replica­
tion process should also be simple," says O'Donnell. 
"But over time, the study of this process has shown 
that nothing could be further from the truth."-+ 
BY JOSEPH BONN ER 
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holoenzyme dimer with a 
polymerase on each 
Leading strand 
replicates as continuous 
DNA segment 
Lagging strand 
replicates in short 
DNA fragments 
called Okazaki 
fragments 
strand 
� clamp 
subunit 
The structure of DNA-the so­
called double helix that James 
Watson and Francis Crick teased 
out in 1953-is made up of four 
building blocks called nucleotides. 
Represented by the letters A, T, G 
and C, the nucleotides pair-A 
• SEARCH
new Okazaki 
fragment 
with T, C with G-to form limitless 
combinations along each mirror­
image strand of the double helix. 
The sequence of the letters in this 
alphabet determines the biological 
messages that differentiate all living 
organisms . 
unzips at replication fork 
B 
� clamp 
Clamp loader 
places f3 clamp on each 
RNA fragment to initiate 
extension of Okazaki 
fragment 
RNA 
f3 clamp tethers 
polymerase to 
DNA for rapid DNA 
synthesis 
completed 
Okazaki fragment 
With the discovery of DNA's com­
plementary structure, scientists 
suggested that for DNA to copy 
itself into new cells, the double 
helix might separate into individual 
strands, with each strand acting as a 
template for the creation of a new 
ILLUSTRATION BY TERESE WINSLOW 
complementary strand. 
Little was known about the 
mechanisms behind DNA replica­
tion until the late 1950s, when 
Stanford University's Arthur 
Kornberg isolated an enzyme from 
the baterium E. coli that he called 
DNA polymerase. (For this discov­
ery he shared the 1959 Nobel Prize 
in physiology or medicine.) 
Polymerase was long thought to 
blage called a clamp loader places 
the � subunit on each fragment. 
Dubbed a "sliding clamp," the � 
subunit completely encircles the 
fragment's double helix and freely 
slides along the DNA surface, tether­
ing the polymerase machinery to the 
DNA for rapid synthesis. 
The clamp loader quickly moves 
from fragment to fragment, placing a 
clamp on each primed segment. 
processes as the repair of DNA. He 
also works on piecing together the 
replication process in humans. 
Because evolution conserved the 
molecular machinery in bacteria, 
yeast and people, many of the 
components are similar albeit more 
complex. "The polymerase in 
humans is very similar to the one in 
E. coli, but there are important dif­
ferences," says O'Donnell. "Several
"The elegantly simple structure of DNA sugge.sts that the replication process 
should also be simple. But nothing could be further from the truth." 
be the main enzyme responsible for 
replication in E. coli, but scientists 
now know that more than a dozen 
proteins, known collectively as the 
replisome, work in concert to rapid­
ly and accurately duplicate bacterial 
chromosomes. 
The replisome comprises many 
enzymes, including the primase, 
the helicase and DNA polymerase 
(see figure). In bacteria, replication 
begins at a distinct point in the 
chromosome called the origin, 
where several proteins gather to 
unwind and unzip the DNA into 
separate strands. 
The helicase encircles the 
replication fork, a Y-shaped region, 
or growing point, that translocates 
the parental DNA helix as it 
unwinds. The polymerase moves 
with the replication fork, but the 
DNA polymerase only replicates in 
one direction, and as a result, only 
one strand, called the leading 
strand, is copied in one continuous 
segment. 
The other strand, called the lag­
ging strand, is replicated in short 
pieces called Okazaki fragments. At 
the replication fork, the primase 
produces a short stretch of RNA to 
"prime" the synthesis of each 
Okazaki fragment. A protein assem-
-MICHAEL O'DONNELL 
The polymerase comes in and works 
with the clamp to extend the frag­
ment. The clamp loader disengages 
and moves on to the next primed 
fragment. 
"This is where the polymerase 
really begins to look like a machine," 
says O'Donnell. "You can think of it 
as a ratchet, where it produces 
the strand by making a fragment, 
popping off the helix, going back, 
making a fragment, popping off, 
again and again." 
A major part of O'Donnell's 
research involves determining what 
the gears in the DNA replication 
machinery look like. Since the early 
1990s, when he was at Cornell 
University Medical College, 
O'Donnell has collaborated with RU 
Professor and HHMI Investigator 
John Kuriyan to solve the three­
dimensional structures of many 
of the proteins that replicate 
DNA in bacteria. To date, the two 
scientists and their colleagues have 
determined the structures of six 
. replication proteins, including the 
ring-shaped� subunit and subunits 
of the clamp loader. 
O'Donnell is working on under­
standing how the bacteral replica­
tion machinery interfaces with 
other proteins that perform such 
of the human replication proteins 
have yet to be discovered. For exam­
ple, it is still uncertain what enzyme 
performs the helicase function, 
although most scientists expect one 
will be found." 
O'Donnell also expects to find 
differences in the events that take 
place at the origin. Yeast chromo­
somes, like those in humans, are 
linear rather than circular. Scientists 
have identified specific origins in 
yeast, but the human origin 
complex remains elusive. 
As O'Donnell and other 
scientists uncover more details 
about human DNA replication, 
new weapons will emerge in the 
fight against diseases like cancer. 
Some may target specific proteins in 
the replication machinery, acting 
likea molecular monkey wrench in 
the gears. 
But cancer is a tricky disease, 
cautions O'Donnell. "If you tried 
to inhibit the polymerase, for 
example, you would also inhibit 
normal cells that divide, like the 
cells in the lining of the gut or those 
that make blood cells," he says. "It 
is important in cancer therapy to 
find drugs that are much more 
sophisticated, that will target only 
the cancer cell." • 
SEARCH 
name: Roderick MacKinnon 
• SEARCH 
laboratory: Molecular Neurobiology and Biophysi cs 
area of study: Structure and function of ion channels 
• ponng over 
T.HE MYSTERIES OF
ion channels 
P
rofessor Roderick MacKinnon set up his 
Laboratory of Molecular Neurobiology and 
Biophysics at Rockefeller with a specific goal 
in mind-to obtain a high-resolution three­
dimensional structure of a potassium ion channel pro­
tein. He fully expected that his quest for the structure 
would be a long-term undertaking, requiring at least a 
few years. But less than two years after his arrival here, 
MacKinnon has already accomplished his mission, as 
evidenced by the image of the X-ray crystallographic 
structure of an intact potassium channel protein on 
the cover of the April 3, 1998 issue of Science.
MacKinnon, who was appointed an investigator 
with the Howard Hughes Medical Institute last year, 
modestly attributes his success to "some very lucky 
breaks and extremely hard work on the part of my 
entire laboratory." 
Outside experts, however, are far more forthcom­
ing with their praise for this achievement-"A 
remarkable accomplishment," proclaimed Clay 
Armstrong of the University of Pennsylvania, who -+ 
BY NEE RAJA SAN KARAN 
SEARCH -. • 
reviewed MacKinnon's paper in the 
same issue of Science. "It is a dream 
come true for biophysicists." 
Ever since their discovery in the 
1950s, ion channels have been the 
subject of intense interest to many 
scientists because of the key role 
they play in maintaining some of the 
body's most vital functions. Seated 
in the oily layers of the cell mem­
brane that preserves the integrity of 
each cell, these proteins govern the 
flow of different ions such as potas­
sium, sodium and calcium into and 
out of cells. The proper balance 
of these ions is essential for 
fundamental operations such as the 
transmission of nerve impulses 
throughout the body and brain. 
Shaped like tiny doughnuts float­
ing in oil, the ion channels perform 
the dual functions of gateway and 
gatekeeper. The holes in the dough­
nut form the gateway through which 
the ions flow. However, these holes, 
or pores, are endowed with special 
properties that enable different 
channel proteins to be selective as to 
which ions they allow passage. Like 
security guards who check ID before 
allowing entrance, these molecular 
gatekeepers only allow specific ions 
to pass through their pores. 
What allows the ion channel 
proteins to work as they do? This is 
the question that has engaged 
MacKinnon for over a decade, 
beginning with his observation of an 
experiment monitoring the electrical 
activity of a potassium channel, 
when he was a medical student just 
contemplating a switch to basic 
science. He joined the laboratory 
of his undergraduate mentor 
Christopher Miller at Brandeis 
University, where, as a postdoc, he 
began to work on biophysical 
aspects of channel function. He 
chose to focus specifically on the 
protein selective for potassium ions, 
because it happened to be the target 
• SEARCH 
Ball-and-stick model of a potassium channel from the bacterium Streptomyces lividans looking down 
the pore, which has a potassium ion (red sphere) positioned inside it. The protein is composed of four 
identical subunits surrounding a central pore. The overall molecular architecture is expected to be 
preserved in all known potassium channels. 
of Miller's lab and also because, at 
the time, it was the least-studied ion 
channel, says MacKinnon. 
Beginning with electrophysiologi­
cal and biochemical approaches, 
MacKinnon studied the interaction 
of the potassium channel with a 
specific toxin derived from scorpion 
venom and deduced that the toxin 
inhibited the flow of ions by sitting 
directly on the pore of the channel. 
This led to questions about which 
specific regions of the channel 
proteins bind to ions and the toxins. 
Investigations along those lines 
became possible after 1987, when 
scientists cloned the genes for 
potassium channels in fruit flies. 
In the wake of this development, 
MacKinnon turned to the field of 
molecular biology. By systematically 
mutating the channel gene at specif­
ic locations and observing the­
effects on the channel's ability to 
bind to the specific ions, he was- able 
to pinpoint ion-binding capacity to a 
single region of the protein. 
"All potassium channel proteins 
contain a little signature stretch of 
about 8 to 10 amino acids, which is 
specific for the ion," explains 
MacKinnon. "The sequence is 
conserved across evolution from 
bacteria to humans. In fact, some of 
these proteins have no features in 
common except for this signature. 
It's as if biology chose only one way 
to select for potassium ions." 
Meanwhile, genetic evidence 
suggested that a single potassium 
channel consisted of multiple 
protein subunits. MacKinnon deter­
mined that a functional channel has 
four identical subunits that join 
together like the staves of a barrel 
around the central hole. Each of the 
subunits contains the ion-specific 
signature sequence, "which forms a 
loop extending into the center of the 
hole to create a pore selective for 
potassium ions," he explains. 
The pore-forming loops seemed 
to govern specific functions such as 
ion selectivity, but without a clear 
channel proteins in much larger 
quantities than had been possible," 
remarks MacKinnon. 
Armed with sufficient amounts of 
channel protein, the scientists could 
turn their attention to tackling their 
other problem, namely growing good 
crystals. Historically, membrane­
bound proteins like ion channels 
have been notoriously bad candidates 
for protein crystallograph
y, 
because 
the detergents used to separate such 
proteins from lipids-a necessary step 
in making good protein c�ystals­
often destroy the proteins as well. 
"To give an idea of the labor 
involved in determining the ideal 
parameters for growing good crys-
ions, which are smaller, do not fit 
properly in the cavity. "The oxygens 
in the pore cannot get as close to 
the sodium as they do to potassium. 
Consequently sodium ions are better 
stabilized by oxygens in water mole­
cules and do not enter the pore," 
MacKinnon adds. 
The channel structure also sug­
gests an explanation for the seeming 
paradox of a channel protein's ability 
to reconcile high ion selectivity with 
high throughput, or the rapid flow of 
ions through the channel. 
"The two properties seem incom­
patible because high selectivity 
implies that the interaction between 
the channel and ion must be a 
The channel structure also suggests an explanation for the seeming paradox 
of a channel protein's ability to reconcile high ion selectivity with high throughput, 
or the rapid flow of ions through the channel. 
idea of the 3-D structure of the 
channel, MacKinnon says there was 
no way to test the truth of this idea. 
So he came to Rockefeller where he 
hoped to master crystallographic 
techniques and solve the structure 
of the potassium channel. 
The very nature of the problem 
led MacKinnon and others to antici­
pate slow progress in their work. A 
basic requirement for protein crystal­
lography is that scientists have 
sufficient quantities of the starting 
material or protein, in order to grow 
crystals for X-ray analysis. But 
although potassium channels are 
present in virtually all cells, they are 
usually produced in low quantities. 
Fortunatel
y, 
this hurdle was over­
come when a group of scientists 
discovered and cloned a potassium 
channel from the bacterium 
Streptomyces lividans, using the very 
signature sequence that MacKinnon 
had discovered a few years earlier. 
"The bacterial system cleared the 
path by giving us a way to express 
tals, we concocted a crystal screen 
with a total of 900 different condi­
tions at two different temperatures 
and with 10 detergents," says 
MacKinnon. "Luckily we hit on the 
right combination relatively early." 
The structure of the potassium 
channel (see figure) confirms 
MacKinnon's theory about the 
pore-loop structure determining 
ion selectivity and also offers an 
explanation as to why the channel 
prefers potassium over sodium ions. 
"Basically the potassium selectivity 
filter is a cylindrical cavity lined 
by slightly charged oxygen atoms 
which, in turn, are held in place by 
structural elements in the portion 
of the channel protein that traverses 
the membrane," explains 
Mac Kinnon. 
This structure confers a certain 
rigidity to the cylinder and deter­
mines the diameter of the oxygen­
lined pore. A charged potassium ion 
fits neatly into the narrowest config­
uration of this cylinder. Sodium 
strong one, which would not be 
conducive to letting the ions escape 
past the protein into the cell," 
MacKinnon says. 
But it appears as though the 
selectivity pore resolves this paradox 
by placing two ions near each other 
where they experience mutual 
repulsion by virtue of their electric 
charge. "This suggests that the 
strong attractive forces between 
the potassium ions and channel 
are counteracted locally by the 
repulsive forces between two 
positively charged potassium ions, 
which allows each ion to fall 
through at a rapid rate," he adds. 
Having solved the elusive struc­
ture of the channel, MacKinnon 
plans to obtain information about 
channel structure at still higher 
resolutions and probe other aspects 
of their function. Ultimately, he 
says, "My aim is to figure out 
how channel proteins function as 
the electrical impulse generators 
in biology."• 
SEA�CH 
- I 
name:Ali Hemmati-Brivanlou 
• SEARCH
laboratory: Molecular Vertebrate Embryology 
area of study: formation and patterning of the vertebrate embryo 
challenging 
THE CONCEPT OF EMBRYONIC 
cell fate 
determination 
hat causes cells taken from a particular 
region of an early embryo to become 
nerve cells in some situations and skin 
cells in others? This is a question that 
has puzzled embryologists throughout most of the 20th 
century The answer, arrived at by Associate Professor 
Ali Hemmati-Brivanlou, head of the Laboratory of 
Molecular Vertebrate Embryology at The Rockefeller 
University, holds the potential to yield new methods 
to inhibit tumor formation, treat neurodegenerative 
diseases and improve plastic surgery 
As early as the 19th century, the search was on for 
the answers to this intriguing puzzle. Even without the 
aid of the powerful imaging technology currently avail­
able, embryologists were able to draw astonishingly 
accurate fate maps, detailing embryonic development 
and cell migration. One such fate map showed that 
cells from the dorsal, or back side, of the outermost-+ 
BY URMILA RANADIVE 
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layer of an early embryo were des­
tined to become the nervous system, 
while cells from the ventral, or front 
side, would differentiate into the 
epidermis, or skin. 
In 1924, German embryologists 
Hans Spemann and Hilda Mangold 
used these potentially neural and 
epidermal cells to perform experi­
ments that would garner Spemann a 
Nobel Prize. Spemann and Mangold 
took a small number of cells from the 
dorsal-equatorial region of an early 
embryo and implanted them into the 
ventral side of a different embryo. 
What they got was an embryo with 
two heads and two main body axes, 
including two complete nervous sys­
tems. Because the second nervous 
system derived from cells that would 
normally have become epidermis, 
the scientists concluded the trans­
planted dorsal cells were sending 
signals telling the host ventral cells 
to be neural. The researchers called 
the transplanted signaling region an 
organizer. Embryologists spent the 
next 70 years trying unsuccessfully 
to find the molecule that told 
epidermal cells to become neural. 
Following on a project that he 
started during his postdoctoral 
studies with Douglas Melton at 
Harvard University, Hemmati­
Brivanlou finally solved the problem 
at Rockefeller. He realized that 
Spemann and Mangold had worked 
under an incorrect assumption. 
Cells, even from the ventral side of 
an embryo, do not become epider­
mal by default. Rather, without any 
external signal, cells become neural. 
A decade ago three groups inde­
pendently observed an interesting 
phenomenon that proved key to 
Hemmati-Brivanlou's research. They 
found that if cells of an early embryo 
are removed and grown in such a 
way that they do not conta_ct each 
other, they become neural tissue. 
In considering these results, 
• SEARCH 
DORSAL 
VENTRAL 
ANTERIOR 
POSTERIOR 
Eight-hour old frog embryos stained for the 
expression of the neural inhibitor BMP4 (blue). 
At this time, as a first step toward the establish­
ment of neuronal progenitors, BMP4 is removed 
from the dorsal side of the embryo, which is the 
future side of the central nervous system. 
Hemmati-Brivanlou and then-RU 
Research Associate Paul Wilson 
recognized that the consequence of 
separating embryonic cells was the 
same as that of blocking communi­
cation within an intact group of 
such cells. "When the cells were 
dissociated or couldn't communicate 
they became neural," says Hemmati­
Brivanlou. "But in the embryo, where 
the cells contact each other and 
communicate, they can become epi­
dermal. For the first time we realized 
that to get epidermal cells we should 
look for a negative signal, one that 
told the cells not to become neural." 
Hemmati-Brivanlou works with 
the cells of the frog Xenopus laevis to 
track embryonic development. Its 
1-mm diameter egg is one of the
biggest cells in the world, making it
an ideal candidate for study. Using
Xenopus cells, Hemmati-Brivanlou
identified the bone morphogenetic
protein, BMP4, as a signal inhibiting
neural development. This molecule,
for which Hemmati-Brivanlou
received a patent, delivers two
messages simultaneously: First, it
tells the cells not to become nerve
cells, and second, it tells them to
become skin cells. Since the discov­
ery of BMP4, two related neural
inhibitors, BMP2 and BMP7, have
been identified by Atsushi Suzuki, a
postdoctoral fellow in the Hemmati­
Brivanlou laboratory.
But a further riddle appeared in the 
form of an embryological catch-22. In 
the embryo, ectodermal cells some­
times become neural-even if they 
remain intact and are able to trans­
mit the BMP4 signal to one another. 
So Hemmati-Brivanlou reasoned that 
to get neural cells, you must inhibit 
the neural inhibitor, BMP4. 
So far, three inhibitors of neural 
inhibitors have been identified. These 
are called neural inducers, and all 
three are secreted factors expressed 
primarily in Spemann's organizer. The 
Hemmati-Brivanlou lab discovered 
and cloned one of the neural induc­
ers, known as follistatin, for which it 
also received a patent. The other two 
neural inducers are noggin and 
chordin. Noggin was discovered and 
cloned by William Smith, together 
with Richard Harland, Hemmati­
Brivanlou's doctoral advisor, at the 
University of California at Berkeley. 
Chordin was discovered and 
cloned by Yoshiki Sasai and Eddy 
De Robertis of the University of 
California at Los Angeles. 
Noggin and chordin have been 
found to bind directly to BMP4, 
preventing it from getting to its recep-
Lateral view of a two-day 
old frog tadpole showing a 
subset of cells of the embryonic 
nervous system (red). 
tor on ectodermal cells. The finding 
that noggin and chordin generate 
neural fate by eliminating the activi­
ty of BMP4 provided independent 
evidence for the claim originally 
forwarded by Hemmati-Brivanlou. 
Follistatin's mode of action is still 
under investigation. 
Identifying these factors is only 
the beginning. Now the Hemmati­
Brivanlou lab must determine the 
window of time and space in which 
the ectodermal cells can respond to 
these factors. BMP4, for instance, 
induces ectodermal cells to become 
skin cells in the early embryo. But 
in adult cells, that same BMP4 is 
involved in forming bone. The time 
frame during which cells will 
become skin in response to BMP4 
has not yet been determined. 
Defining the window of opportu­
nity for neural inducers is even 
more difficult. "How can one put a 
time limit on a default fate, one that 
would occur in the absence of all 
other molecular factors?" Hemmati­
Brivanlou asks. 
Epidermal or neural induction 
can occur on many levels. Factors 
from outside or inside the cell may 
influence transcription-the synthe­
sis of RNA out of DNA-and trans­
lation-the conversion of an RNA 
sequence into proteins. The 
Hemmati-Brivanlou laboratory aims 
to understand what happens down­
stream of BMP4's activity. How does 
BMP4 tell a cell not to become 
neural? How does it tell the cell to 
instead become epiderm�l? 
Scientists know that BMP4 binds 
to a receptor on the surface of a cell. 
The binding acts as a trigger for a 
signal that gets passed from the 
receptor to the nucleus. "Like 
runners in a relay race," explains 
Hemmati-Brivanlou, "signal 
transducing proteins called SMADs 
pass the signal baton along until it 
reaches the nucleus." 
SMADs can also work as signal 
blockers. So even if BMP4 binds to 
the surface of a cell, certain SMADs 
can act as internal inhibitors, revers­
ing the fate of the cell back to neural. 
But if the epidermal inducing 
signal does get transduced all the 
way to the nucleus, it affects the 
transcription of DNA. Inside the 
nucleus, the signal turns on the 
genes involved in skin formation 
and turns neural genes off. 
Postdoctoral Fellow Atsushi 
Suzuki has identified msxl as the 
first gene to get turned on when the 
BMP4 signal to make epidermis 
arrives at the nucleus. Another 
postdoctoral fellow in Hemmati­
Brivanlou's lab, Daniel Weinstein, 
has identified and cloned a gene, 
called eIF-4AIII, which regulates 
translation of BMP4's signal. The 
eIF-4AIII gene had never been 
cloned before in an animal and is in 
the works as another patent for the 
Hemmati-Brivanlou lab. 
In addition to adopting a given 
fate, embryonic cells also have the 
continuous task of maintaining their 
identity. Maintenance can be 
achieved through positive feedback 
loops or by extracellular signals, 
provided by neighboring cells. 
Though their focus is basic 
research, the Hemmati-Brivanlou 
laboratory's findings have many 
potential applications. Their patent 
on BMP4 is essentially a patent for 
epidermal induction. The ability to 
create skin promises to be beneficial 
for plastic surgery, burn victims and 
wound healing. 
The other side of the epidermal 
induction coin is neural inhibition. 
BMP4 is part of the TGF�, or trans­
forming growth factor-beta famil
y, 
and acts as a strong neural inhibitor, 
explains Hemmati-Brivanlou, "so 
brain tumors or spinal tumors are 
obvious targets for BMP4 treatments." 
Some of the SMADs are neural 
inhibitors that work downstream of 
BMP4 and could be used to prevent 
the growth of tumors of neural origin. 
Finally, neural inducers like 
follistatin, noggin and chordin 
represent promising treatments for 
neurodegenerative diseases like 
Alzheimer's and Parkinson's, in 
which the regeneration of dying 
neural tissue would be beneficial. 
For now, Hemmati-Brivanlou says 
he will leave the applications of his 
findings to other scientists and clini­
cians, while he continues to focus 
on basic research. • 
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iological clocks are ubiquitous in 
nature, influencing everything from 
a tree's tendency to shed its leaves in 
autumn to a bird's decision to head 
south for the winter. A master clock 
ticks within each of us as well-a biological 
timepiece that guides us through the dail
y,
24-hour circadian cycle of sleep and wakeful­
ness. It is this clock that leaves us fighting jet
lag when we travel across time zones, then
forces us to sleep no matter how much work
we have left to finish. The biological clock
also maintains an indirect control over other
cyclic processes in the body, regulating,
among other things, the daily waxing and
waning of body temperatures and hormone
levels. While these daily fluctuations help us
make the transition from sleep to wake, they
also make it more likely for events such as
heart attacks or asthma attacks to occur at
certain times of the day.
Professor Michael Young, head of the 
Laboratory of Genetics at The Rockefeller 
University, says he has been fascinated with 
nature's timekeeper since he was a junior -+ 
BY URM I LA RANADIVE 
high school student. He earned 
his B.A. in biology in 1971 and in 
1975 his Ph.D. in genetics at the 
University of Texas at Austin, where 
he noticed new work on the genetics 
of circadian rhythmicity. Several years 
later, after postdoctoral work in bio­
chemistry at Stanford Medical School, 
he moved to RU and turned once 
again to this longtime interest, setting 
out to understand the molecular 
underpinnings of the biological clock. 
By 1984, Young had cloned a 
gene named period (per) of the fruit 
fly Drosophila that appeared to affect 
snowshoe hares, exist in highly 
synchronized, 10-year population 
cycles. For example, suppose the 
cycle begins when the lynx 
population has hit bottom: With few 
predators, the number of hares rises, 
supporting an ever larger lynx popu­
lation to prey on the hares. As food 
supplies plummet, however, fewer 
lynx survive, and once again the 
hare population rebounds. 
Although not an animal 
behaviorist, Young observed the 
interdependent interactions of the 
lynx and hare populations and saw 
so, how. He went into this research 
armed with a few key observations. 
First, the TIM protein was rhythmic. 
That is, TIM followed the same 
cycle as PER protein. Second, 
cycling of the PER protein did not 
occur in flies with a mutation of the 
tim gene. The key to the puzzle lay 
in a significant observation made by 
Leslie Vosshall, a doctoral student in 
Young's laboratory. 
"Leslie's work was our first 
indication that there really was a 
close partnership between these two 
proteins, TIM and PER," says Young . 
... the per and tim partnership is so close that their daily cycling cannot occur 
without their two proteins, PER and TIM, working in concert. 
circadian rhythms. A homolog, or 
descendant copy, of this gene has 
recently been isolated in humans by 
research teams at the University of 
Tokyo's Institute of Medical Science 
and Baylor College of Medicine. 
"Based on this discovery, I'd say 
it's likely that the genes, proteins 
and mechanisms emerging from 
Drosophila are telling us how our 
own pacemakers work," says Young. 
But in 1984, Young was still 
struggling to understand why per 
was important for rhythms. Young 
knew that the gene was needed for 
circadian rhythms because flies that 
expressed a per mutation in their 
brain's pacemaker cells had disrupted 
cycles of activity and rest. Colleagues 
at Brandeis University had shown that 
the mutations also blocked the cyclic 
synthesis of the per-coded PER pro­
tein. But it was unclear how, in nor­
mal flies, the gene made a product 
that was produced in a cyclical, rather 
than constant pattern. 
In solving the puzzle, Young 
recalled a phenomenon involving 
biological oscillations of a very 
different kind. Two animal popula­
tions, lynxes and their primary prey, 
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a model for his molecular clock. 
Perhaps interdependence was the 
key: Was there a gene that influenced 
per, causing its levels to rhythmically 
rise and fall? 
L ooking for a second gene to work hand-in-hand with per involved screening tens of 
thousands of Drosophila for individ­
uals with aberrant sleep/wake cycles. 
Adult fruit flies normally hatch from 
their pupal shells at dawn, so Young 
was on the lookout for flies emerg­
ing at any other time of day-those 
that probably had a mutation in a 
gene involved in the circadian 
rhythm. This process led to the 
identification, and eventually the 
cloning, of a gene called timeless 
(tim). Young's laboratory has since 
uncovered tim's pivotal role in the 
molecular clock. In fact, the per and 
tim partnership is so close that their 
daily cycling cannot occur without 
their two proteins, PER and TIM, 
working in concert. 
But when tim was first identified, 
Young had a lot of work ahead of 
him. He had yet to determine 
whether tim worked with per, and if 
Vosshall noticed that although tim 
mutants-those that did not have the 
tim gene-made per RNA, she could 
not detect any PER protein. However, 
when she fused the PER protein to a 
very stable enzyme, she detected the 
fused PER protein. But it was pro­
duced in a constant pattern, without 
the daily fluctuations normally 
found in Drosophila. More intriguing 
was that in tim mutants, the fused 
PER protein was produced in the 
cytoplasm, but never appeared in 
the nucleus. In normal Drosophila, 
the PER protein cycles in and out of 
the nucleus. 
Based on these and other obser­
vations, Young's laboratory worked 
out PER and TIM's interdependent 
relationship as follows: Normally, 
PER and TIM proteins are at their 
greatest concentration in the 
nucleus of the cell shortly before 
dawn. After hitting their peak 
concentrations, the proteins begin to 
disintegrate and leave the nucleus. 
When the cell perceives the declin­
ing concentration of the proteins, it 
signals the per and tim genes to begin 
making RNA that will produce more 
proteins. Although the RNA accumu-
-1
PER/Tl M complex 
Cell from circadian 
pacemaker region 
offly brain 
MIDNIGHT 
per gene 
• As PER/TIM complexes accumulate
in nucleus, cell stops producing per 
and tim RNA and blocks further accumulation of 
PER/TIM complexes.
Translation of tim RNA 
into Tl M protein 
TIM protein 
ILLUSTRATION BY TERESE WINSLOW 
cytoplasm 
per RNA 
DAWN 
• No transcription of per or tim genes into RNA. 
• Many PER/TIM protein complexes 
are in nucleus. Disintegration begins.
PER/TIM 
complex 
PER 
protein 
DUSK 
NOON 
• PER/TIM protein complexes 
disappear from nucleus. 
• per and tim genes begin transcribing 
RNA but. no translation occurs.
tim RNA 
• Peak levels of per and tim RNA in
cytoplasm produce high levels of PER
and TIM proteins.
• Initial binding of PER and TIM proteins
begins.
Translation of per RNA 
into PER protein 
lates throughout the day, very little 
nu_clear protein amasses during this 
time. Instead, PER and TIM abrupt­
ly appear in the nucleus shortly after 
dusk, long after RNA levels hit their 
peak. As the proteins build up 
inside the nucleus, they trigger a 
negative feedback loop telling the 
per and tim genes to stop making 
RNA. At dawn, the cycle begins 
anew with the disintegration of the 
accumulated proteins. 
The pace of the clock is set by 
the time lag between the transcrip­
tion of the genes' DNA to RNA and 
the subsequent nuclear appearance 
of PER and TIM. Young's laboratory 
has identified the key contributors 
to this lag. First, the researchers 
discovered that the PER and TIM 
proteins must join together in the 
cytoplasm in order to enter the cell's 
nucleus. Their second discovery 
hinged on two significant factors: 
First, Vosshall observed that the 
PER protein is rapidly broken down 
in the cytoplasm when it is not 
paired with TIM, and second, they 
identified a new gene, named dou-
• SEARCH
The Drosophila clock protein TIMELESS accu­
mulates to high levels in nuclei of the eyes and 
certain cells of the brain at night (top), but is 
rapidly destroyed when the fly is briefly exposed 
to light (bottom). 
bletime (dbt), which regulates this 
process (as reported in Cell, July 10, 
1998). The result is that PER pro­
tein levels are actively held down, 
even as RNA levels are rising. 
Add to this another complicating 
factor. The cytoplasm of the cell 
contains factors that also compete 
for the attention of PER. Newly 
made PER proteins have cytoplasmic 
localization domains (CLDs) that 
inhibit movement to the nucleus by 
holding them in the cytoplasm. It 
just so happens that PER's CLD is in 
the same area as its TIM binding site. 
During the day, TIM is not pre­
sent in high enough concentrations 
to successfully compete for PER's 
CLDs. This is because TIM is a 
light-sensitive protein. So while 
PER's CLDs hold it in the cytoplasm, 
allowing the unpaired proteins to 
be actively destroyed, TIM is being 
removed by light. 
The scenario changes at dusk, 
when there is no light to destroy the 
TIM protein as it is being produced 
by its RNA. At this point, TIM 
accumulates in large enough quantity 
to capture PER before it is snatched 
by the CLDs and degraded in the 
cytoplasm. Thus bound, and only 
after this union, can the PER/TIM 
complex enter the nucleus. 
"Requiring that the PER and TIM 
proteins be paired before entering 
the nucleus is a good way of ensur­
ing a lag between the time that the 
tim and per genes are transcribed to 
the time that the TIM and PER 
proteins can reenter the nucleus 
and suppress the transcription of 
their genes," explains Young. "So 
we find several regulatory steps that 
collaborate to give the per and tim 
genes a long period during which 
they are not inhibited by their 
protein products." 
But it is light-sensitive TIM that 
determines the clock's period in a 
natural environment. TIM needs 
light-though not a full 12 hours­
to maintain a 24-hour clock. The 
interval of light, which can reset the 
clock no matter where the body is in 
the circadian cycle, need only be 
long enough to completely degrade 
TIM and allow a sufficient buildup 
of RNA to restart protein production. 
How do pacemaker cells detect 
light? In the fly, Young thinks, pace­
maker cells in the brain have their 
own photoreceptors that detect 
light and influence the circadian 
cycle. The photoreceptor system is 
more complicated in mice and 
humans, who have more complex 
brain structures. Pacemaker cells in 
these two animals are located in the 
suprachiasmic nucleus (SCN), a 
conglomeration of neurons in the 
brain's hypothalamus. The sleep/ 
wake cycle is probably controlled 
by PER and TIM cycling in these 
pacemaker cells, which are never 
directly exposed to light. But the 
proteins have also been found in 
the mammalian retina, which has 
its own clock. So communication 
between clocks in the eyes and 
brain may keep behavior in register 
with the environment. 
A host of unanswered questions 
remain about how fluctuations of the 
PER and TIM proteins in pacemaker 
cells affect an animal's sleep/wake 
cycle. Young reasons that the cycling 
of the per and tim genes will be 
echoed in the cycling of other genes 
in the cell. During the last few years, 
scientists have paid special attention 
to clock control genes (CCGs). The 
activity of these genes oscillates with 
the circadian rhythm, establishing 
cycles in the production of other 
hormones, transcription factors and 
in�racellular components. The CCGs 
are influenced b
y, 
but do not them­
selves affect, the rhythm of the clock. 
An example of a CCG is a gene 
that produces N-acetyl transferase, 
an enzyme required for melatonin 
synthesis. Because the transcription 
of this gene cycles up and down in 
concert with per and tim cycles in 
the pacemaker cells, melatonin is 
produced in cycles. Melatonin, a 
hormone that causes drowsiness, 
has a direct effect on the sleep/wake 
cycle (see Melatonin Miracle, p. 23).
"We imagine that as we build a 
bigger catalog of the products of 
these CCGs, we'll have a pretty 
good indication of the cascade of 
events that can drive the whole 
behavioral response to the biological 
clock," says Young. 
T he biological clock regulates more than just the sleep/wake cycle. All kinds of 
hormones are produced in rhythms, 
peaking at set times during a 24-
hour period. The biological clock 
also controls the progression of 
events during a 24-hour interval, 
ensuring that event A occurs before 
event B, which precedes event C. In 
this way, an organism can anticipate 
the time of day both behaviorally 
and physiologically (see Circadian 
Call to Arms, this page). 
Recent studies have demonstrat­
ed the existence of independent 
clocks throughout the bod
y, 
indicat­
ing that time of day is important to 
all parts of the bod
y, 
not just the 
brain. Steve Kay at The Scripps 
Research Institute, for example, 
showed that leg, wing and antennae 
tissue from Drosophila will continue 
to rhythmically produce PER and 
TIM in the absence of any input 
from the fly's central nervous sys­
tem. Other researchers have shown 
that in eye tissue removed from 
mice, the retina will continue to 
secrete melatonin with a 24-hour 
circadian rhythm. 
"You've got cells all over the body 
that find it very important to pay 
attention to time of day," says 
Young, "important enough to keep 
track of time locall
y, 
instead of having 
to depend on a central integrating 
pacemaker like the one in the brain 
that controls the overall sleep/wake 
behavior." 
of human circadian rhythms. His 
research may also provide a basis for 
therapies to treat afflictions that are 
influenced by circadian rhythms. 
Timing medical treatments to the 
body's natural rhythm, for example, 
could become an important new 
therapeutic tool. Researchers have 
found that cancer patients, for 
instance, can be as much as 10 times 
more sensitive to a chemotherapeu­
tic drug at one time of day than they 
are at another. 
This sensitivity might result from 
the variable concentrations of other 
hormones and factors influenced by 
the circadian clock. Drug regimes 
are currently being created that 
specify time of delivery in addition 
to dosage and frequency. 
Recent studies have demonstrated the existence 
of independent clocks throughout the body, indicating 
that time of day is important to all parts of the body, 
not just the brain. 
Further evidence to support the 
importance of time-keeping can be 
found in nature, where activities 
controlled by the circadian rhythm 
extend from the turning of leaves in 
autumn to foraging and hibernation 
patterns of animals. These seasonal 
changes depend on an organism's 
measuring and comparing day 
length against its internal circadian 
oscillator. 
Noting the use of biological clocks 
by nearly all organisms, scientists 
think that these clocks have been 
highly conserved throughout evolu­
tion. For example, a counterpart to 
the fruit fly's per gene has been found 
in mice. And the recently discovered 
homolog of the per gene in humans 
is further evidence that the compo­
nents of the clock are highly 
conserved among species, making it 
likely that Young's Drosophila research 
will result in a better understanding 
Preventive measures could also be 
developed for asthma and heart 
attacks, which occur more frequently 
at specific times of the day. Treat­
ments for jet lag and insomnia might 
also come from Young's research. 
But for now Young's interests will 
take him back to the PER/TIM 
protein complexes in the cell's 
nucleus. "For us, there are still 
important unsettled questions: 
How much of the Drosophila clock 
system is conserved in human pace­
maker cells? How is the rate of the 
molecular cycle regulated with an 
accuracy of minutes? Can our 
discovery of the molecules forming 
this clock take us directly to the 
genes that affect behavior in a time­
dependent fashion?" Young is stick­
ing to fruit flies, looking to identify 
and understand the function of the 
remaining components of the 
molecular clock. • 
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1:00 a.m. 
• Pregnant women are most likely
to go into labor. 
• Lymphocytes are at their peak.
2:00 a.m. 
• Growth hormone levels are highest.
4:00 a.m. 
• Asthma attacks are most likely.
6:00 a.m. 
• Onset of menstruation is most likely.
• Plasma insulin is lowest.
• Blood pressure and heart rate begin to
rise rapidly.
• Cortisol (stress hormone) levels begin
to rise.
• Melatonin levels begin to fall.
7:00 a.m. 
• Symptoms of allergic rhinitis (hay fever)
are worst.
8:00 a.m. 
• Calories are burned most readily.
• Risk for heart attack and stroke is
highest.
• Symptoms for rheumatoid arthritis
are worst.
• Lymphocytes are at their lowest
daytime level.
noon 
• Level of hemoglobin in blood peaks.
3p.m. 
• Grip strength, respiratory rate and
reflex sensitivity highest; good time
for athletes.
4p.m. 
• Body temperatures, pulse and blood
pressure peak.
6p.m. 
• Urinary flow is highest.
9p.m. 
• Pain threshold is lowest.
11 p.m. 
• Skin is most reactive; allergic response
most likely.
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of an infecting virus. Hanafusa 
presented the following problem to 
Kuriyan: How did mutations in this 
single gene change the functioning 
of its protein product to induce a 
cell to start developing tumors? 
Kuriyan, now Patrick E. and 
Beatrice M. Haggerty Professor, head 
of the Laboratory of Molecular 
Biophysics and a Howard Hughes 
Medical Institute investigator, has a 
vivid memory of Hanafusa introduc­
ing him to the Src problem by draw­
ing a straight line on the blackboard 
and blocking out different regions, 
representing different parts of the 
molecule. Based on biochemical and 
genetic analyses, Hanafusa knew 
Increasing 
the Magnification 
of Discovery 
Technology led the way to 
discovery of the src gene. 
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about mutations in different parts of 
the src gene that resulted in the 
"transformation" of normal cells to 
cancerous types, but he did not have 
a precise picture of how these muta­
tions altered the normal activity of 
the Src protein. 
One of the most significant 
breakthroughs toward answering 
this question came last year, when 
Kuriyan's group, as well as Stephen 
Harrison's laboratory at Harvard 
University, solved the crystal struc­
tures of two Src proteins. The 
achievement represents an impor­
tant milestone, not only with respect 
to answering specific questions 
about Src activity, but also because 
Peyton Rous 
Discovers tumor 
agent, later called 
Rous Sarcoma Virus 
(RSV), that can 
transmit cancer in 
chickens. 
of Src's leading role in the history of 
understanding the general mecha­
nisms underlying cancer. It is a story 
with deep roots at Rockefeller, datip.g 
back to the turn of the century 
when Peyton Rous discovered the 
first tumor-inducing virus, thereby 
providing future cancer researchers 
with an indispensable tool for prob­
ing cell behavior and its breakdown. 
Rous came to RU-then the newly 
founded Rockefeller Institute for 
Medical Research-in 1909 on the 
invitation of the first director, Simon 
Flexner, to head a laboratory for 
cancer research. Within a few weeks 
of his arrival, a chicken breeder 
brnught a chicken to Rous's labora­
tory. The bird had a large growth 
that he recognized as a sarcoma 
tumor. Knowing that fowl tumors 
had not yet been studied in any detail, 
Rous began a thorough analysis of 
its properties and pathologic effects. 
Rous found that the tumors were 
transplantable over several genera­
tions and began to search for a 
causative agent within the tumor 
cells. Using new freeze-drying tech­
niques developed by his colleague, 
James Murphy, Rous broke open the 
tumor cells, filtered the contents to 
ensure the complete removal of 
intact cells and injected this cell-free 
material into chickens to see 
whether they developed sarcomas. 
In a now classic paper entitled "A 
Sarcoma of the Fowl Transmissible 
by an Agent Separable from the 
Tumor Cells," published in The 
] ournal of Experimental Medicine in 
1911, Rous described the tumor 
agent for the first time and speculat-
James Murphy 
Proposes that RSV 
is a transmissible 
mutagen. 
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"The first tendency will be to regard the self-perpetuating agent active in this 
sarcoma of fowl as a minute parasitic organism." 
-PEYTON ROUS, THEjOURNAL OF EXPERIMENTAL MEDICINE, 191 l
ed on its identity. 
"The first tendency will be to 
regard the self-perpetuating agent 
active in this sarcoma of fowl as a 
minute parasitic organism," he 
wrote, hinting at the possibility that 
the tumor agent was a virus. In 
1966 Rous received a Nobel Prize for 
his discovery of the Rous Sarcoma 
Virus (RSV). Within the scientific 
community, however, there appears 
to have been little early acceptance 
for the idea that a virus could cause 
cancer. In 1931 Murphy published a 
paper in which he proposed that the 
tumor-inducing agent was perhaps a 
"transmissible mutagen," whose 
mode of activity was to induce per­
manent mutations in the host cells 
that resulted in cancer. 
As is turned out, the two ideas 
were not mutually exclusive. 
Murphy's idea that mutations led to 
cancer was indeed correct. RSV, as 
scientists learned, served as one of 
the vehicles that introduced specific 
tumor-inducing mutations into the 
cell. Other mutagens s�ch as chemi­
cals and radiation could also cause 
mutations that initiated cancer. But 
neither of these agents produced 
consistent results with respect to the 
type of tumor that was formed. So, 
for a new generation of scientists, 
RSV served as the main vehicle for 
the molecular analysis of cancer. 
As tumor virologist Harry Rubin 
remarked in 1966, " ... what else if not 
tumor virology can lead to an under­
standing of the molecular basis for 
Photograph of a chicken (c. 1911) in which Rous induced a tumor using a filtered cell extract containing RSV 
Harry Rubin 
and Howard Temin (Caltech) 
Develop an assay for RSV in tissue 
culture which opens up genetic and 
biochemical analysis of tumor viruses 
Identification of src gene as 
tumor-inducing component 
of RSV. 
the malignant behavior of cells?" 
In 1958 Rubin and Howard 
Temin at the California Institute of 
Technology in Pasadena developed a 
method to assay RSV in tissue cul­
ture. This gave scientists a quantita­
tive handle on the virus and allowed 
them to monitor changes induced 
by the virus directly at the cellular 
level, rather than having to inject a 
whole animal and wait for tumors to 
develop. It enabled scientists to map 
out the entire RSV genome and 
assign specific functions to specific 
genes. As a postdoc in Rubin's 
laboratory at the University of 
California, Berkeley, during the early 
1960s, Hanafusa was an active par­
ticipant in the analysis of mutants 
deficient in their ability to cause 
transformation-which eventually 
led to the identification of src as the 
single gene required for inducing 
cellular transformation. 
At the outset, the discovery of src
opened up more questions than it 
answered. How did it induce trans­
formation? The gene was obviously 
not required for either viral replica­
tion or survival- so why did it exist 
at all? What function did the gene 
and its protein product serve? 
In 1976 Michael Bishop and 
Harold Varmus at UC, San Francisco, 
found that a version of the viral src
(called v-src) gene was present in 
normal uninfected cells. Hard on the 
D. Stehelin, M. Bishop
and H. Varmus (UCSF)
Discover that a version of src exists 
in the DNA of normal, uninfected cells. 
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" ... what else if not tumor virology can lead to an understanding of the molecular 
basis for the malignant behavior of Gel ls?" -HARRY RUBIN, TUMOR VIROLOGIST, 1966
heels of this discovery, Hanafusa, 
who had moved to Rockefeller in 
1973, furnished the genetic evidence 
that cellular src (c-src) sequences 
did in fact substitute for the trans­
formation function missing in defec­
tive RSV mutants. To achieve this, 
he injected uninfected chickens with 
mutants of RSV that were known to 
have lost most of the DNA from 
their src gene and looked for the 
development of tumors. 
"My prediction was that viruses 
containing partial deletions of the 
src sequence would undergo recom­
bination with cellular sequences at a 
tumor tissue, Hanafusa found he 
could recover viruses with complete 
src genes that were evidently derived 
from the host cell and not from the 
original sarcoma virus. 
The discovery of c-src and v-src 
played a major part in reconciling 
the seemingly disparate theories of 
the viral and mutational origins of 
cancer in the following manner: The 
normal cell contains a gene with the 
potential for inducing cancer, but 
this gene-the protooncogene-can 
cause transformation only after it 
was mutated to form an oncogene. 
All known cancers can be traced 
A schematic representation of the Src protein highlighting its principle domains and tyrosine phospho­
rylation sites. The green segments correspond to the protein fragment structure pictured on page 31. 
higher rate and thus be able to 
produce tumors," explains 
Hanafusa, who is now Leon Hess 
Professor and head of the Jeanette 
Warren Davidson Laboratory of 
Molecular Oncology. 
Sure enough, the chickens inject­
ed with these mutants developed 
tumors that differed from the 
original sarcomas in two major 
respects: They appeared two months 
rather than a week after the injec­
tions and developed very far away 
from the site of inoculation of the 
virus. Upon examining the new 
Hidesaburo Hanafusa (at Rockefeller) 
Finds that non-tumorigenic RSV can 
become tumorigenic after picking up 
cellular src DNA. 
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to mutations in some normal 
protooncogene. 
Once scientists discovered the 
existence of cellular and viral src 
genes (and proteins), they naturally 
turned their attention to investigating 
the differences in the two forms that 
caused such a drastic change in their 
transformation capabilities. By 1987, 
Hanafusa and others had conducted a 
systematic comparison of the DNA 
and protein sequences of cellular and 
viral src and identified the major dif­
ferences. They pinpointed the critical 
difference to a single amino acid in 
Analysis of the differences 
between cellular and viral src 
DNA and protein sequences. 
the tail region of the protein-a tyro­
sine present at position 527 of c-Src 
and missing from v-Src. 
But even this discovery failed to 
answer the crucial question of how 
the absence of a single amino acid 
changed the protein to a form that 
induced cellular transformation? 
Investigators looking into functional 
aspects of src had determined that 
the normal gene encoded a key 
component of the network of molec­
ular signals that regulate growth and 
development patterns of a cell. Src 
functions as a kinase-a protein that 
transfers phosphate molecules to 
other cellular proteins and activates 
them-ultimately sending a message 
to the cell to start dividing. Kinases 
must be very tightly regulated or else 
cell division can run amok, resulting 
in cancer. In c-Src this regulation was 
found to be linked directly to Tyrosine 
5 2 7: When this amino acid was 
phosphorylated, the protein appeared 
inhibited, while removal of the phos­
phate from this site resulted in an 
elevated activity. 
This observation immediately 
suggested that v-Src induced trans­
formation by permanently removing 
the internal brake from the cellular 
protein. Hanafusa o�tained further 
evidence in support of this idea 
when he discovered a portion of the 
molecule called SH2 near the head of 
the Src protein, which has a special 
affinity for binding with phosphory-
Identification of regulatory regions 
(SH2 and SH3) in oncogenes 
Hanafusa proposes model for Src 
regulation by interactions within protein. 
"The whole enzyme appears to be functioning like a Rube Goldberg machine, 
employing many complex parts to perform a simple task." -JOHN KURIYAN 
lated tyrosine 111olecules. The discov­
ery had two exciting implications. 
First, it suggested that the SH2 
region could bind to the phosphory­
lated Tyrosine 527, like a snake 
biting its own tail. An intramolecu­
lar contortion of this kind, Hanafusa 
imagined, would block Src's active 
site-its kinase domain-and thus 
prevent it from phosphorylating 
other proteins. The finding also 
indicated that the SH2 domain 
played the role of a molecular 
postman, who recognized specific 
intracellular addresses-the tyro­
sines-where the kinase delivered 
the phosphate molecules. When 
attached to the internal tyrosine, the 
postman could no longer reach the 
other addresses, which resulted in 
the suppression of Src activity. 
This then was the model that 
Hanafusa presented to Kuriyan in 
1989: A linear diagram of the Src 
protein with its component domains 
and the position of the key muta­
tions, superimposed with biochemi­
cal information on the possible areas 
of interaction. 
"The question that Saburo posed, 
very simply and directly, was 'How 
is Src regulated?"' recounts Kuriyan. 
"To proceed any further with under­
standing how it worked, one needed 
to know what it looked like in three 
dimensions." 
The researchers had their first 
breakthrough when Kuriyan and his 
Collaboration of several Rockefeller 
laboratories. Determination of the 
3-D crystal structure of SH2 region
of Src.
Three-dimensional crystal structure of the Srcfamily kinase Hck. The molecule is seen here in its 
inhibited form with the phosphotyrosine at position 527 bound to the SH2 domain. SH3 and kinase 
domains are also identified. 
collaborators s�lved the crystal 
structure of a v-Src SH2 domain in 
1992. The structure immediately 
clarified the way in which SH2 
domains could recognize phospho­
tyrosine molecules and provided the 
first bit of support for Hanafusa's 
proposed mechanism of control. 
Then last year, Kuriyan, along 
with postdocs Ismail Moarefi and 
Frank Sicheri, published the com­
plete crystal structure of Hck-a 
Src-related molecule found in white 
blood cells-showing how the 
unmutated molecule looks in its 
regulated state. In the broadest 
John Kuriyan lab 
Determination of 3-D crystal 
structure of Src-family protein Hck. 
sense, the structure confirms the 
validity of Hanafusa's conjectures 
that the Tyrosine 527 plays a key 
role in regulation by binding with 
SH2. In addition the structure 
reveals other, subtler details about 
interactions within the Src molecule, 
which contribute to the integrity of 
the overall structure. 
"The whole enzyme appears to be 
functioning like a Rube Goldberg 
machine, employing many complex 
parts to perform a simple task," 
explains Kuriyan. 
What next? "While our under­
standing of individual components 
such as Src and Hck is now quite 
advanced, there are hundreds of 
such proteins that are communicat­
ing with each other to regulate cell 
behavior," says Kuriyan. "The big 
challenges ahead lie in understand­
ing how the cells integrate and sort 
through this multiparty system of 
communication." • 
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SCIENCE AND OTHER NEWS FROM THE ROCKEFELLER UNIVERSITY CAMPUS 
Study shows 
estrogen may prevent 
onset of Alzheimer's 
BY LJ RM I LA RANADIVE 
Alzheimer's disease, the devas­tating illness that leads an esti­mated 4,000,000 Americans 
through progressive and irreversible 
declines in mental function, occurs 
in postmenopausal women at a two­
fold higher incidence than in males 
of the same age. During the last few 
years, retrospective epidemiological 
studies have shown that a history of 
estrogen replacement therapy in 
women after menopause was associ­
ated with a reduction, by about 50 
percent, in the risk of developing 
Alzheimer's. 
Alzheimer's disease is character­
ized by the buildup of plaques, 
which are primarily made up of 
p amyloid proteins, in the brain. 
These p amyloid plaques are widely 
regarded as the key to the disease. 
In a study published in the April 
1998 issue of Nature Medicine, a 
research group led by RU Professor 
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Cortical neurons that were treated with estrogen (above) produced less plaqueforming, � amyloid 
protein than neurons that were not exposed to the hormone. 
Paul Greengard, along with members 
of RU Professor Brian Chait's labora­
tory and researchers at other institu­
tions, demonstrated that exposure to 
estrogen correlates with a decrease in 
p amyloid protein production. 
In making the link between 
estrogen and P amyloid, the 
Greengard lab's study provides the 
first molecular basis for understand­
ing why estrogen therapy works. It 
also supports the continued use of 
estrogen replacement therapy, which 
is already widely employed to treat 
and prevent osteoporosis in post­
menopausal women and which has 
also been found to protect healthy, 
older women against heart attacks. 
Greengard's study also showed 
that estrogen need only be replaced 
at premenopausal levels and that the 
longer a woman is treated with the 
hormone, the greater the degree of 
protection against Alzheimer's disease. 
1 7P-estradiol, the form of 
estrogen used by Greengard and his 
colleagues in this study, is one of a 
family of molecules that includes 
the male sex hormones. In fact, 
testosterone is a precursor of 
estrogen and is the major source of 
estrogen in men. 
Greengard and his colleagues 
plan to test other compounds, 
including testosterone and estrogen 
analogs, for their effectiveness, 
since estrogen therapy itself has 
been associated with increased risk 
of developing blood clots and cer­
tain types of cancer. 
Now that the researchers have 
established that estrogen reduces 
the production of p amyloid, the 
next step is to understand how. 
The Greengard laboratory's strat­
egy is to look inside the cell to see 
where the p amyloid forms-before 
and after treatment with estrogen­
to see where estrogen might inter­
cede in the metabolic pathways. 
"If we are successful in elucidat­
ing the intracellular p amyloid 
production location and the molec­
ular apparatus that is responsible 
for the reduction of the P amyloid, 
this will provide new targets for 
drugs that will be effective in 
treating the disease," says 
Greengard, who directs the univer­
sity's Zachary and Elizabeth M. 
Fisher Center for Research on 
Alzheimer's Disease. 
Funding sources for this research 
included the National Institutes of 
Health, the Alzheimer� Association 
and the Fisher Foundation. 
Immature dendritic 
cells (far left) 
engulfing influenza­
infected monocytes 
(middle). 
Rockefeller researchers develop method to fight 
tumors using dendritic cells BY JosEPH BONNER 
D endritic cells patrol the body's borders, guarding against outside invaders by capturing, 
processing and presenting antigens 
to the body's T cells. Dendritic cells 
also capture mutated pieces of the 
body's own tissue from tumors as 
well as normal self-tissue. Most 
importantly, they are able to initiate 
immune responses to either fight or 
tolerate these molecules. 
These findings-published in the 
March 5 Nature by Bhardwaj and 
her coauthors, Biomedical Fellow 
Matthew Albert and Postdoctoral 
Fellow Birthe Sauter-widen the 
possibility of using dendritic cells to 
treat human tumors, viruses and 
infections. 
Using the influenza virus as a 
model system-because the flu 
vaccine induces only antibodies and 
Assistant Professor Nina Bhardwaj (left) has been working with Biomedical Fellow Matthew Albert and 
Postdoctoral Fellow Birthe Sauter to harness the dendritic cell's antigen-presenting ability to fight tumors. 
Recently, a team of researchers 
from the Laboratory of Cellular 
Physiology and Immunology, led by 
Assistant Professor Nina Bhardwaj, 
found a new way to harness the 
dendritic cell's antigen-presenting 
abifity to fight human tumors. 
not killer T cells-the researchers 
found they could take dendritic 
cells, infect them with influenza 
virus and elicit killer T cells in 
culture very efficiently from normal 
individuals. The cytolytic killer T 
cell, also known as the CDS+ cell, 
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plays a key role in eradicating 
viruses, such as HIV, and in tumor 
immunity. Autoreactive killer cells 
(cells capable of recognizing the 
body's own cells or antigens) must 
in turn be tolerized, or turned off, 
to prevent autoimmune disease. 
During the course of these stud­
ies, the researchers found that if 
they took other antigen-presenting 
cells, like macrophages, and infect­
ed them with influenza, the cells 
die from the infection. 
In fact, the cells undergo a 
process called apoptosis, a type of 
cell suicide or programmed death. 
Because they die in culture, the 
apoptotic cells do not get a chance 
to efficiently present antigens to 
T cells. 
Further experiments showed that 
an influenza-infected apoptotic 
macrophage, cocultured with an 
uninfected dendritic cell and T cells 
from someone who had been previ­
ously exposed to influenza, allowed 
the dendritic cell to acquire the 
influenza antigens and trigger killer 
T cells. 
"Our hope is to be able to take 
blood donations from a patient and 
grow dendritic cells from precursor 
cells in the blood," says Albert. 
"We can then charge or pulse the 
dendritic cells with apoptotic cells 
and reinject them into the patient to 
induce activated T cells. 
"The discovery of this new path­
way," he continues, "allows the den­
dritic cell's natural machinery to 
decide which pieces of the protein 
are useful to an individual's immune 
system." 
Funding for this work was 
provided in part by the National 
Institute of Allergy and Infectious 
Diseases, part of the federal govern­
ment� National Institutes of Health 
(NIH), and by the NIH Medical 
Scientist Training Program. 
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THE HYDROGENOSOME AT 25: 
New hypothesis points to organelle's role in 
evolution of eukaryotic cells 
A new hypothesis coauthored by Associate Professor Miklos Muller and published in the 
March 5 Nature may change the way 
evolutionary biologists look at the 
origins of eukaryotic cells. 
The classic theory of eukaryotic 
evolution contends that eukaryotes 
descended from proto-eukaryotes, 
single-celled organisms that already 
possessed a nucleus to hold their 
genetic endowment. These ancestral 
organisms contained inner mem­
branes and a cytoskeleton that 
enabled them to eat and digest 
other anaerobic prokaryotes, but 
contained no mitochondria. 
Sometimes the engulfed bacteria 
was assimilated and became an 
endosymbiont-an internal partner 
in a mutually beneficial relation­
ship-assisting the host in respira­
tion and receiving nourishment 
and physical protection in return. 
The endosymbiont became the 
mitochondrion, the cell's energy­
producing powerhouse. 
With their "hydrogen hypothe­
sis," Muller and his coauthor, 
William Martin, a plant biologist 
from the Institute for Genetics at 
the Technical University in 
Braunschweig, Germany, suggest 
that eukaryotes arose through the 
need to share the machinery of 
energy metabolism for survival and 
not by an evolutionary roll of the 
dice. According to Muller and 
Martin, the first host was a 
methanogen, a single-celled organ­
ism that produces methane by 
consuming hydrogen and carbon 
dioxide. The endosymbiont derived 
from a bacterium that produced 
hydrogen as waste, an ancestor of 
the mitochondrion and a cell 
organelle called the hydrogenosome . 
Hydrogenosomes, discovered at 
Rockefeller in 1973 by Muller and 
Donald Lindmark, are found in 
single-celled organisms that lack 
mitochondria, so-called amitochon­
driates. Living free or in multicellu­
lar hosts, these microscopic entities 
live in inhospitable environments­
digestive and urinary tracts, mud, 
sulfur springs-and produce hydro­
gen as waste. 
An electron micrograph of a cell taken from a 
parasite called a trichomonad reveals an 
organelle called the hydrogenosome (arrows). 
The researchers suggest that the 
methanogen and the bacterium that 
provided its "fuel of life" met in a 
hydrogen-rich environment. The 
pair, separated from the hydrogen 
source by an unknown means, 
survived by gradually integrating 
and becoming structurally and func­
tionally dependent on each other. 
"The future symbiont possessed 
hydrogenosomal function and the 
host used the hydrogen and carbon 
dioxide produced by it," explains 
Muller. "This is the link that forged 
integration." 
Funding for this work was provid­
ed by the National Institutes of 
Health.-). B. 
RU researchers elucidate 
stress response in 
plants BY MARGUERITE LAMB 
H ow do plants respond to stresses brought on by drought? Last December, 
Nam-Hai Chua, Andrew W Mellon 
Professor and head of RU's 
Laboratory of Plant Molecular 
Biology, and members of his labora­
tory announced in the journal 
Science that they had come one 
step closer to elucidating this 
vital process, having uncovered an 
important piece of the plant stress­
response puzzle. 
Scientists have long known that 
a plant's ability to endure environ­
mental challenges depends on 
stress hormones such as abscisic 
acid (ABA), which signals the 
release of intracellular calcium, in 
turn activating a variety of stress­
response genes. 
Usuall
y, 
a number of molecules­
including receptors, proteins and 
iments, postdoctoral fellow Yan Wu, 
along with her coauthors and fellow 
Chua lab postdocs Randy Foster and 
Eric Man�chal, demonstrated cADPR's 
role in ABA signal transduction. 
The researchers began by inject­
ing the stems of tomato seedlings 
with either of two ABA-sensitive 
Next, to show that cADPR is pre­
sent and active in plants, Man�chal, 
along with coauthor and former 
postdoctoral fellow Jennifer Kuzma, 
attached one of the stress-response 
genes to Iuciferase, the gene that 
makes fireflies glow, and transferred 
this gene into a tiny plant called 
Scientists have long known that a plant's ability to endure environmental challenges depends 
on stress hormones such as abscisic acid, which signals the release of intracellular calcium 
and activates a variety of stress-response genes. 
messengers-will fill key positions 
along the signal-transduction 
pathway, passing the message one 
to the next. But until recently, the 
molecular bucket brigade linking 
ABA to calcium to ABA-responsive 
stress genes had remained largely a 
mystery. 
That mystery began to be unrav­
eled last winter, when Chua and 
his RU team reported that it had 
definitively-and for the very first 
time-located a second messenger 
molecule called cyclic ADP-ribose 
(cADPR) in the ABA signaling 
pathway. 
Through a series of tomato exper-
stress genes. They used a third, 
light-activated gene as a control. 
Prior to injection, all three genes 
had been attached to a reporter 
gene, which gives off a telltale blue 
hue when activated with a substrate, 
allowing researchers to monitor its 
activity, as well as the activity of the 
genes to which it is linked. 
The researchers demonstrated 
that ABA and cADPR, introduced 
individually into the altered plants, 
can induce expression of the stress­
responsive genes. Yet inhibitors of 
either cADPR or calcium will stop 
stress-gene expression, even in the 
presence of ABA. 
Arabidopsis thaliana. The 
researchers then introduced ABA 
and monitored the plant's tissue for 
a revealing glow. 
Gene expression peaked after 
four to eight hours of exposure to 
ABA. And, as the researchers had 
suspected, activation of this gene 
was preceded by a rise in the levels 
of cADPR, manifested by a rush of 
calcium ions. 
The team's findings hint at 
intriguing possibilities for the world 
of agriculture and beyond, since 
cADPR is believed to be an active 
messenger in a variety of cell 
systems, including those of humans. 
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Glucose metabolism defect identified in rare form 
of Type 2 diabetes 
I n December 1996, Assistant Professor Markus Stoffel, in collaboration with researchers 
at the Howard Hughes Medical 
Institute at the University of 
Chicago and the University of 
Michigan Medical Center, mapped 
MODYl, a particularly rare but 
severe form of Type 2 diabetes, to a 
gene called HNF4a. Less than a year 
later, Stoffel and a colleague in the 
Laboratory of Molecular Cell 
Biology identified the mechanism of 
this defect, which impairs the path­
way that breaks down blood sugar 
and provides the main signal for 
insulin secretion in the pancreas. 
This work, reported in the Nov. 25, 
1997 Proceedings of the National
Academy of Sciences, provides the 
first insight into the molecular mech­
anism of this disease and opens new 
avenues for developing better thera­
pies to treat more common forms of 
late-onset diabetes. 
Diabetes affects the way sugar is 
taken up and metabolized by cells. In 
the pancreas, � cells secrete insulin, 
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the hormone that promotes absorp­
tion of glucose and other nutrients by 
cells. When glucose increases in the 
bloodstream-for example, after eat­
ing-a molecule in the� cell called 
the glucose transporter-2 takes up the 
sugar. T he pancreatic� cells then 
sense the glucose concentration, 
break glucose down and provide a 
signal for insulin production and 
secretion. As glucose increases in the 
blood, insulin secretion increases. 
T here are two major forms of dia­
betes. Type 1 diabetes occurs when 
the body's immune system destroys 
� cells. Type 2 diabetes, the more 
common type accounting for more 
than 90 percent of cases, is caused 
by ineffective insulin secretion or 
improper insulin action on target 
tissues such as muscle, leading to 
impaired glucose uptake from the 
blood and increased levels of blood 
glucose. 
Genes are some of the most 
important risk factors for Type 2 
diabetes, although environment also 
plays a role in the disease. Most 
common forms of diabetes are poly­
genic, meaning that more than one 
gene is involved in the disease, mak­
ing it difficult to identify the genes 
responsible. But in about 1 to 3 per­
cent of cases, inheritance follows a 
classic autosomal dominant pattern: 
Anyone in a family who has one 
copy of the defective gene is likely 
io develop hyperglycemia, or 
increased levels of blood glucose. 
Known as maturity onset-diabetes of 
the young (MODY), this form of 
diabetes usually develops before age 
25. Scientists have found four dia­
betes genes, each linked to a differ­
ent form of MODY.
In the new study, Stoffel and co­
author Stephen A. Duncan, formerly 
an assistant professor in Professor 
James E. Darnell Jr.'s laboratory, 
showed that the defect in HNF4a 
that causes MODYl is a loss of 
function mutation, meaning that the 
disease develops due to the inactiva­
tion of this gene. 
"We have also shown that there 
is gene-dosage effect-if the gene's 
activity is decreased, there is a cor­
responding reduction in a related 
transcription factor called HNFla, 
which is important for insulin 
production," explains Stoffel. 
Both HNFla and HNF4a belong 
to a class of proteins called tran­
scription factors, molecules that 
switch other genes on or off. In the 
early 1990s, Darnell's laboratory 
identified HNF4 and showed that it 
regulates gene expression in the 
liver, kidney and intestine. 
Stoffel and Duncan developed a 
novel technique to study the effect 
of HNF4a on glucose transport and 
metabolism. Using embryonic stem 
(ES) cells-cells found in early 
stages of the embryo that can theo­
retically turn into any tissue in the 
body-the researchers produced 
clumps of about 2,000 cells that 
contain the visceral endoderm and 
later develop into the yolk sac. 
Genes that are expressed in the 
liver, like HNF4a, are also 
expressed in the visceral endoderm. 
The yolk sac, which is the main tis­
sue that produces insulin during 
development, acts like a gut, pro­
viding nutrients to the embryo. 
This feature makes the visceral 
endoderm a good model to study 
pancreatic � cells, explains Duncan. 
"The visceral endoderm provides 
a physiological system for the 
genetic dissection of metabolic 
pathways," says Stoffel. 
Most common forms of 
diabetes are polygenic, mean­
ing that more than one gene 
is involved in the disease, 
making it difficult to identify 
the genes responsible. 
When HNF4 was removed from 
the visceral endoderm, the scientists 
found a decrease in activity of sev­
eral genes that act at different stages 
of the insulin-secretion signaling 
and insulin-production pathway. 
These new findings suggest that 
drugs designed to target HNF4a 
activity could lead to improved 
treatments for Type 2 diabetes. 
"Activating HNF4a would lead 
to an increased expression of the 
glucose transporter-2 and the 
enzymes of glucose metabolism, 
increasing the rate of glucose 
metabolism and increasing insulin 
production and secretion," says 
Stoffel. 
Stoff el is an Irma Hirschl Scholar, a 
Pew Scholar and Robert and Harriet 
Heilbrunn Professor. Duncan is a 
Naomi Judd American Liver Scholar 
and an Alexandrine and Alexander 
Sinsheimer Scholar. This work was 
supported by the American Diabetes 
Association. -J.B. 
New research challenges 30 years of dogma 
on treating lupus and other autoimmune diseases 
For the more than 500,000 Americans with systemic lupus erythematosus, the only thera­
pies for this devastating autoimmune 
disease are ineffective and nonspecific 
antiinflammatory and immune-sys­
tem suppressing drugs. But research 
from the laboratory of Professor 
Jeffrey V Ravetch, reported in the 
Feb. 13 Science, overturns a 30-year­
old dogma and may change the way 
doctors treat patients with lupus. 
The disease causes severe inflam­
mation and kidney disease. Lupus 
develops when the immune system 
attacks the body's own tissues by 
producing autoantibodies directed 
against its own cells. The new 
research identifies a critical link 
between autoantibodies and inflam­
mation and suggests novel ways of 
uncoupling this connection. 
"These studies show that pre­
venting the activation of antibody 
receptors by autoantibodies is an 
effective way to treat autoimmune 
diseases like lupus," says Ra vetch, 
who is the Theresa and Eugene M. 
Lang Professor and head of the 
Leonard Wagner Laboratory of 
Molecular Genetics and Immunology. 
The traditional dogma on how 
autoantibodies caused disease in 
lupus is based on a component of 
the immune system called the com­
plement system, which scientists 
thought triggered inflammation. 
But research from the Ravetch lab 
and elsewhere during the last few 
years has pointed to an alternative 
pathway in which scientists think 
that Fe receptors, antibody-binding 
molecules that are crucial to both 
triggering an immune response and 
to turning off the response once the 
threat has been eliminated, play an 
important role. 
In the new research, Ravetch and 
his coauthors, Research Associate 
Raphael Clynes and graduate 
researcher Calin Dumitru, bred Fe 
receptor-deficient mice to a strain of 
mice that spontaneously develop a 
disease closely matching human 
lupus. The researchers found that 
82 percent of mice without the Fe 
receptor were alive after nine 
months, as compared to less than 20 
percent of lupus mice with an intact c. 
Fe receptor. 
Ravetch and his colleagues found 
evidence of immune complexes and 
a complement protein called C3 in 
the kidneys of both strains of mice, 
but the Fe receptor-deficient mice 
showed no evidence of inflammato­
ry disease. 
"These results indicate that Fe 
gamma receptors are required for 
the initiation of the inflammatory 
cascade and complement activation 
is not sufficient," says Ra vetch. 
"These findings argue for the devel­
opment of new therapeutic strate­
gies for the treatment of lupus based 
on blocking Fe receptors." 
This work was supported by the 
National Institute of Allergy and 
Infectious Diseases and the National 
Institute of Diabetes and Digestive 
and Kidney Diseases, both part of the 
federal governments National 
Institutes of Health. -J. B; 
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Mutated gene causes death of nerves in brain 
BY MARION E. GLICK 
A gene responsible for the degeneration and death of certain nerve cells in the brain 
has been cloned by investigators 
from the laboratory of RU Professor 
Nathaniel Heintz and The Johns 
Hopkins School of Medicine. 
The gene carries instructions to 
make a receptor for neurotransmit­
ters, which nerve cells use to 
communicate, and its isolation may 
be useful for further studies of such 
diseases as Alzheimer's and Parkin­
son's. The discovery, resulting from 
mouse studies, marks the first time 
scientists have identified and directly 
linked a mutant gene in the gluta­
mate receptor family to the death of 
brain cells. Because of the mutation, 
the resulting faulty receptor acts as if 
a neurotransmitter always is 
present-even when none of the 
chemical is there. This false detection 
causes the nerve cells to die. 
"The mutations in the 82 gluta­
mate receptor gene may play a role 
in changing the metabolism of the 
adult nerve cells to reactivate a 
program of cell death that normally 
occurs only during natal develop­
ment. If we can reveal more about 
this process and understand it, it 
may be possible to slow down or 
stop the process and preserve the 
neuron," explains Heintz, head of 
the Laboratory of Molecular Biology 
and an investigator at the Howard 
Hughes Medical Institute. 
During fetal development, pro­
grammed cell death is used to sculpt 
the final number of cells in the 
mature brain. About twice as many 
cells begin the process of developing 
into neurons than are needed in an 
adult brain. Consequently, many of 
the cells activate a biochemical 
program to commit suicide, known 
as an apoptotic death, because they 
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receive certain chemical signals. 
"We think that the surveillance 
mechanisms that monitor the 
normal metabolism of neurons are 
much like those monitoring the 
cell-division cycle in other types of 
cells," says Heintz. "In neurodegen­
erative diseases, these mechanisms 
may activate the apoptotic cell death 
pathway as a normal response to the 
severe dysfunction of neurons. Our 
discovery of the 82 glutamate recep­
tor gene mutation helps us to 
understand how this gene functions 
in normal neurons, but the $64,000 
question remains: 'How does its 
altered function trigger cell death?"' 
The study appeared in the Aug. 21, 
1997 Nature. 
The Howard Hughes Medical 
Institute and the National Institute of 
General Medical Sciences, part of the 
federal government� National Institutes 
of Health, fundefl this research, with 
support from the National Institute of 
Mental Health, the McKnight 
Foundation, the Derelbiss Fund and the 
National Alliance for Research on 
Schizophrenia and Depression. 
Support 
University launches 
center for immunology 
studies 
I n January, the university launched the Christopher H. Browne Center for Immunology 
and Immune Diseases. "This 
center will allow us to create an 
integrated program that capital­
izes on the talents of a diverse 
group of investigators, using the 
newest scientific methods to 
study the immune system's 
complexities in ever-increasing 
detail," says Tors ten N. Wiesel, 
M.D., president of the university.
"We are enormously grateful to
Chris Browne for helping us to
launch an initiative that will
have a major impact on this vital
area of biomedicine."
The new center will be direct­
ed by Ralph M. Steinman, M.D., 
Henry G. Kunkel Professor and 
head of the Laboratory of Cellular 
Physiology and Immunology. 
Other members of the center 
include Michel C. Nussenzweig, 
M.D., Ph.D., professor and head
of the Laboratory of Molecular
Immunology and an associate
investigator with the Howard
Hughes Medical Institute
(HHMI); Jeffrey V Ravetch, M.D.,
Ph.D., Theresa and Eugene M.
Lang Professor and head of the
Leonard Wagner Laboratory of
Molecular Genetics and
Immunology; Yongwon Choi,
associate professor, head of the
Laboratory of Immunology and
an assistant investigator with
HHMI; and David D. Ho, M.D.;
professor at Rockefeller and
scientific director of the Aaron 
Diamond AIDS Research Center 
(AD ARC) for the City of New York. 
ADARC affiliated with the university 
in 1996. 
Plans for the Christopher H. 
Browne Center include creation of 
to promote new clinical research on 
an expanded range of immune­
related conditions, particularly 
autoimmune diseases and cancer, 
with the ultimate goal of developing 
more effective therapies. The 
Rockefeller University Hospital, the 
"This center will allow us to create an integrated program that 
capitalizes on the talents of a diverse group of investigators, 
using the newest scientific methods to study the immune 
system's complexities in ever-increasing detail." 
new laboratories at Rockefeller 
focusing on key areas of immunolo­
gy research. Scientists working in the 
center will also have access to 
essential core resources, including a 
facility to study genetically altered 
mouse models that can advance 
understanding of gene function and 
disease states. Other shared resources 
will house state-of-the-art instru­
ments for cell and tissue analysis. 
A principal goal of the center is 
largest clinical research center 
supported by the U.S. National 
Institutes of Health, will play a 
major role in this endeavor. 
Currently, more than 25 clinical 
protocols focusing on immunology 
are under way at the hospital, 
including studies of the drug 
thalidomide, which has proven 
effective in alleviating the wasting 
associated with AIDS and 
tuberculosis. -J.B. 
Kreek lab receives 
$12.3 million grant 
from NIDA 
The National Institute on Drug Abuse (NIDA) at NIH has awarded $12.3 million to The 
Rockefeller University in continuing 
support of a NIDA-NIH Research 
Center established here in 1987, 
under the direction of RU Professor 
Mary Jeanne Kreek, head of the 
Laboratory of the Biology of 
Addictive Diseases. 
"We are absolutely thrilled to 
receive this renewal grant," says 
Kreek, who credits the center's 
"talented team of scientists for work­
ing tirelessly over the last two years" 
to produce the successful proposal. 
"This was an extremely 
competitive process, but we received 
outstanding reviews across the 
board." The center, says Kreek, is 
dedicated to identifying biological 
correlates of addictions to heroin, 
cocaine and alcohol-alone and 
in combination with one another­
while also studying other factors 
that might affect treatment 
outcomes. 
"Effective treatments must be 
based on a fundamental understand­
ing of the molecular neurobiological 
basis of each specific addictive 
disease," she maintains, "as well as 
of the effects of drugs of abuse and 
any inherent and environmental 
factors that may increase vulnerabili­
ty prior to exposure to such drugs." 
Over the next five years, the 
NIDA grant will support the center's 
core resources and six projects to be 
undertaken by scientists in the 
Kreek laboratory.-M. L.
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HONORS 
Professors Jan Breslow and David D. 
Ho were elected to the Institute of 
Medicine of the U.S. National 
Academy of Sciences. Breslow is head 
of the Laboratory of Biochemical 
Genetics and Metabolism. Ho is 
scientific director of the Aaron 
Diamond AIDS Research Center for 
the City of New York. 
A paper on Chagas' disease, 
coauthored by Abby Rockefeller 
Mauze Professor Joel E. Cohen, 
head of the Laboratory of 
Populations, was awarded the Fred 
L. Soper Prize by the Pan American
Health and Education Foundation.
Associate Professor Robert Darnell, 
head of the Laboratory of Neuro­
Oncology, was named the ninth 
recipient of the Derek Denny-Brown 
Young Neurological Scholar Award 
by the American Neurological 
Association. The award goes annual­
ly to "a newly elected member of the 
association who is deemed to have 
achieved a significant stature in 
neurological research and whose 
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promise of continuing major contri­
butions to the field of neurology is 
anticipated." 
Paul Greengard, Vincent Astor 
Professor and head of the Laboratory 
of Molecular and Cellular ' 
Neuroscience, received the 1997 
Charles A. Dana Award for Pioneering 
Achievements in Health, an accolade 
that recognizes "outstanding accom­
plishments that hold great potential 
for fostering positive change in 
health." He shared the award with 
Trustee Eric R. Kandel, university 
professor at Columbia University. 
Alumnus Scott M. Grundy ('68) 
was the winner of the 1997 Bristol­
Myers Squibb/Mead Johnson Award 
for Distinguished Achievement in 
Nutrition Research. 
Leon Hess Professor Hidesaburo 
Hanafusa, head of the Jeanette 
Warren Davidson Laboratory of 
Molecular Oncology, was elected a 
fell ow of the American Academy of 
Microbiology, the only honorific 
leadership group devoted entirely to 
microbiologists and the science of 
microbiology. 
Professor Mary E. Hatten, head of 
the Laboratory of Developmental 
Neurobiology, delivered the keynote 
address at commencement at her 
alma mater, Hollins College in 
Virginia, where she was presented 
with an honorary doctorate. 
The Rockefeller University's Aaron 
Diamond AIDS Research Center 
(ADARC) was awarded a $500,000 
Bristol-Myers Squibb Unrestricted 
Infectious Disease Research Grant to 
help support studies on the dynam­
ics of HIV replication. Professor and 
ADARC Scientific Director David 
Ho will supervise the grant. Ho, 
who was honored by the New York 
Academy of Medicine at its Fourth 
Annual Gala Dinner, gave commence­
ment addresses at Swathmore College 
and at the Massachusetts Institute of 
Technology, where President Clinton 
also spoke. 
Sherman Fairchild Professor 
Attallah Kappas, head of the 
Laboratory of Pharmacology, was 
appointed to a six-year term as a 
member of the Council of the State 
University of New York (SUNY) 
Health Sciences Center in Brooklyn, 
N. Y. The council serves as the 
governing body of the center, which 
includes its medical school and 
graduate education and hospital 
facilities and is the largest health 
science center in the SUNY system. 
Professor and President Emeritus 
Joshua Lederberg, head of the 
Laboratory of Molecular Genetics 
and Informatics, received an hon­
orary Doctor of Military Medicine 
degree from the Uniformed Services 
University of the Health Sciences. 
Alumnus Robert Mackel ('78), 
adjunct faculty member in the 
Asanuma laboratory, has been named 
president of the Council for Higher 
Education in Luxembourg. Charged 
with advising the government on 
policy decisions affecting higher edu­
cation and scientific research, the 
council is comprised of leaders from 
academia, business and industry. 
The National Alliance for Research 
on Schizophrenia and Depression 
(NARSAD) awarded Professor Bruce 
McEwen, head of the Harold and 
Margaret Milliken Hatch Laboratory 
of Neuroendocrinology, a 1998 
Distinguished Investigator grant and 
named Assistant Professor Maria 
Karayiorgou, head of the Laboratory 
of Human Neurogenetics, and 
Barbara Porton, postdoctoral associ­
ate in the Laboratory of Molecular 
and Cellular Neuroscience, recipients 
of 1998 Young Investigat;r awards. 
Bruce Merrifield, John D. 
Rockefeller Jr. Professor Emeritus 
and head of the Laboratory of 
Biochemistry, and university Trustee 
Ronald C. Breslow, professor of 
chemistry at Columbia University; 
were among the top 75 "distin­
guished contributors to the chemical 
enterprise" named by Chemical & 
Engineering News, the news magazine 
of the American Chemical Society. 
Assistant Professor Peter Mombaerts, 
head of the Laboratory of Vertebrate 
Developmental Neurogenetics, was 
named a Guggenheim Fellow by the 
John Simon Guggenheim Memorial 
Foundation. The fellowships are 
awarded to individuals "who have 
demonstrated exceptional capacity 
for productive scholarship or excep­
tional creative ability in the arts." 
He also received a Scholar Award 
from the Rita Allen Foundation and 
was awarded a 1997 Presidential 
Early Career Award for Scientists and 
Engineers (PECASE), one of only 11 
scientists to be granted the award by 
President Clinton. Mombaerts is the 
second Rocke£ ell er faculty member 
to receive the award. Associate 
Professor Ali Hemmati-Brivanlou, 
head of the Laboratory of Molecular 
Vertebrate Embryology, received a 
PECASE in 1996. 
Professor Michael O'Donnell, head 
of the Laboratory of DNA 
Replication and an HHMI investiga­
tor, received a Method to Extend 
Research in Time (MERIT) Award 
from the National Institute of 
General Medical Sciences at NIH in 
support of his study "Biochemical 
Mechanism of DNA Polymerase III 
Holoenzyme." 
Melissa Pope, assistant professor in 
the Laboratory of Cellular Physiology 
and Immunology; and Leonidas 
Stamatatos, assistant professor and 
staff scientist at the Aaron Diamond 
AIDS Research Center, were named 
winners of the American Foundation 
for AIDS Research Award for their 
innovative research on HIV vaccines. 
Andrej Sali, assistant professor and 
head of the Laboratory of Molecular 
Biophysics, was awarded a 1998 
Sloan Research Fellowship by the 
Alfred P. Sloan Foundation. 
President Emeritus Frederick Seitz 
was awarded the Joseph Henry 
Medal by the Smithsonian 
Institution. The medal recognizes 
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Seitz's "exemplary contributions to 
the Smithsonian Institution." 
Henry Kunkel Professor Ralph 
Steinman, head of the Laboratory of 
Cellular Physiology and Immunology, 
received the Cancer Research 
Institute's 1998 William B. Coley 
Award for Distinguished Research in 
Basic and Tumor Immunology. 
Rong Wang, assistant professor in the 
Laboratory for Mass Spectrometry 
and Gaseous Ion Chemistry, received 
a $150,000 grant from the 
Alzheimer's Association to investigate 
the role of metabolism of amyloid 
beta-protein in Alzheimer's disease. 
President Torsten Wiesel is the 
recipient of The New York Academy 
of Medicine's 1998 John Stearns 
Award for Lifetime Achievement in 
Medicine. Presented at the acade­
my's 1998 Spring Stated Meeting, 
the award recognizes Wiesel's "pio­
neering studies of the mammalian 
visual cortex, [ which] have signifi­
cantly shaped current understanding 
of brain structure, function and 
development." 
Alumnus Cecil Cheung-Ching Yip 
('63) received a McMaster Award for 
Science for contributions to insulin 
research. 
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FACULTY 
Markus Stoffel, assistant professor 
and head of the Laboratory of 
Metabolic Diseases, was appointed 
the first Robert and Harriet 
Heilbrunn Professor. The professor­
ship provides support for a member 
of the junior faculty conducting 
research on diabetes. 
PROMOTIONS 
TO PROFESSOR: 
Steve DiNardo, head of the 
Laboratory of Developmental and 
Molecular Genetics. 
Titia de Lange, head of the 
Laboratory of Cell Biology and 
Genetics. 
TO ASSOCIATE PROFESSOR: 
Yongwon Choi, head of the 
Laboratory of Immunology. 
Robert B. Darnell, head of the 
Laboratory of Molecular Neuro­
Oncology. 
Seth Darst, head of the Laboratory 
of Molecular Biophysics. 
Ali Hemmati-Brivanlou, head of the 
Laboratory of Molecular Vertebrate 
Embryology. 
David S. Thaler, member of the 
Laboratory of Molecular Genetics 
and Informatics. 
ADMINISTRATION 
The board of trustees presented 
the David Rockefeller Award for 
Extraordinary Service to The 
Rockefeller University to university 
Trustee John C. Whitehead and 
David J.L. Luck, the late Alfred E. 
Mirsky Professor and vice president 
for academic affairs, who died May 
23, 1998 (see In Memoriam, next 
page). The award recognizes an indi­
vidual from the RU community who 
exhibits an enthusiasm for RU's 
scientists and their research, dedica­
tion to furthering the university's 
mission and strengthening the 
institution, and encourages others to 
support the biomedical sciences for 
the benefit of humankind. It was 
established and first presented in June 
1995 to David Rockefeller, in honor 
of his 55 years of distinguished ser­
vice on the board of trustees. 
Life Trustees Brooke Astor and 
David Rockefeller were each award­
ed a Medal of Freedom, the nation's 
highest civilian honor, by President 
Clinton. 
RU Trustee and Adjunct Professor 
Alexander G. Bearn has been 
named executive officer of the 
American Philosophical Society, the 
oldest U.S. learned society, founded 
by Benjamin Franklin in 1743 to 
"promote useful knowledge" in 
science and the humanities. 
Science Outreach Program Director 
Bonnie Kaiser was elected director­
at-large of the American Chemical 
Society's New York Section for 1998. 
David J. Lyons, senior advisor to 
the president and retired vice presi­
dent for business and finance and 
treasurer at RU, received the 
National Association of College and 
University Business Officers 1997 
Distinguished Business Officer 
Award. 
Research Associate Marguerite 
Mangin is now associate dean of 
graduate studies. She was previously 
assistant dean. Associate Professor 
Thomas P. Sakmar, head of the 
Laboratory of Molecular Biology and 
Biochemistry and an associate inves­
tigator with HHMI, has been named 
associate dean of graduate studies, 
with special responsibility for 
Rockefeller's participation in the Tri­
institutional M.D.-Ph.D. Program. 
Kenneth W Rose, assistant to the 
director of the Rockefeller Archive 
Center, has been awarded a Fulbright 
grant by the United States Information 
Agency to teach American history 
and American studies at Ege 
University in Izmir, Turkey. 
' IN MEMORIAM 
DAVID J.L. LUCK 
The Rockefeller University commu­
nity is mourning the loss of David 
J.L. Luck, Alfred E. Mirsky Professor
and vice president for academic
affairs, who died Saturday, May 23,
at New York Hospital. He was 69
years old. The cause of death was
lymphoma.
Luck was a medically trained 
researcher with a keen interest in 
basic science. After earning a med­
ical degree from Harvard Medical 
School and clinical training at 
Massachusetts General Hospital 
(MGH), Luck came to Rockefeller as 
a graduate fellow in 1958, where he 
joined the cell biology laboratory of 
Nobel laureate George E. Palade. 
His early research focused on how 
growing cells form mitochondria, 
structures contained in the body of 
the cell that produce metabolic ener­
gy. In 1962, Luck and Rockefeller 
biochemist Edward Reich, working 
with the simple mold Neurospora, 
were among the first to discover that 
mitochondria contain their own 
DNA, distinct from the DNA found 
in the cell nucleus. He established the 
existence within mitochondria of a 
class of ribosomes-RNA-protein 
complexes that are the sites for pro­
tein synthesis-that can serve as a 
means for converting the genetic 
information of this unique DNA into 
protein. In the late 1970s, Luck 
showed that one ribosomal protein, a 
component of the small subunit of 
the ribosome, was made within mito­
chondria and regulated the entire 
assembly process of protein synthesis. 
Luck's later research focused on 
microtubules, the dynamic skeletal 
structures that assist cells in move­
ment, communication with other 
cells and division. Using the single­
celled aquatic alga Chlamydomonas 
as a model organism, Luck and his 
associates were able to identify and 
study the function of some of the 
more than 200 accessory proteins 
that are present in flagella and cilia. 
His investigations of microtubules 
in Chlamydomonas provided a 
methodological framework for nego­
tiating the far more complex micro­
tubular systems in human cells and 
toward establishing possible links 
between microtubular failure and 
lung, reproductive or neurological 
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disorders, or in the cell-division 
defects in cancer. 
Luck received a medical degree 
from Harvard Medical School in 
1953. Except for two years of med­
ical service with the United States 
Air Force, he was on the staff of 
MGH between 1953 and 1958 as 
intern, assistant resident, physician 
and resident physician. 
Luck received his doctoral degree 
from Rockefeller in 1962 and 
became a research associate. He was 
appointed assistant professor in 
1964, associate professor in 1966 
and professor in 1968. In 1985 he 
was named the university's first 
Alfred E. Mirsky Professor, and in 
1994, vice president for academic 
affairs. 
Luck was elected to membership 
in the U.S. National Academy of 
Sciences in 1984 and was a fell ow 
of the American Association for the 
Advancement of Science. 
He was a member of the Medical 
Advisory Board of the Howard 
Hughes Medical Institute (HHMI) 
and served on the Scientific Review 
Boards of HHMI (1989 to 1993) and 
the Massachusetts General Hospital 
(1989 to 1992). 
J. RICHARDSON DILWORTH
Trustee Emeritus J. Richardson 
Dilworth died of complications from 
heart surgery on Dec. 29, 1997, at 
Princeton Hospital in Princeton, 
N.J. He was 81. A noted philan­
thropist and financier, Dilworth 
served RU as a trustee from 1960 to 
1991. As treasurer and chairman of 
the university's finance and invest­
ment committee, he helped to 
ensure the financial health of the 
institution and oversaw a fourfold 
growth of its endowment. Dilworth 
played a key role in the develop­
ment of housing for students and 
faculty, as well as the construction 
of new laboratory buildings that 
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transformed the south e'nd of 
campus into a modern biomedical 
research complex. In 1992 Dilworth 
was named a trustee emeritus and 
the following year he was awarded 
an honorary doctor of science 
degree in recognition of his out­
standing service to The Rockefeller 
University community. At the time 
of his death, he was on the board of 
directors of AEA Incorporated, a 
private investment company he 
helped to found. 
KEITH R. PORTER 
Keith R. Porter, a former member 
and professor of the Rockefeller 
Institute for Medical Research who 
is widely recognized as a founding 
father of modern cell biology, died 
May 2, 1997. Porter joined 
Rockefeller as a research assistant in 
1939. In 1953, he became the head 
of the Laboratory of Cytology, later 
renamed the Laboratory of Cell 
Biology. While at RU, Porter 
cocreated the first electron micro­
graph of an intact cell, along with 
Albert Claude and Ernest Fullam. 
Later, Porter identified the cell's 
endoplasmic reticulum, elucidated 
the structure of collagen fibers, cilia 
and microtubules, and defined the 
microtrabecular lattice. His innova­
-tive methodology for the use of the 
electron microscope, design of the 
Porter-Blum microtome and tech­
niques for tissue culturing opened 
up the field of cell biology by allow­
ing much greater insight into the 
structure and function of cells. 
In 1955, Porter founded the 
Journal of Cell Biology, which is 
published by the RU Press. He 
founded the Tissue Culture 
Association in 1946, and in 1961 he 
cofounded and became the first 
president of the American Society 
for Cell Biology Porter was a mem­
ber of the National Academy of 
Sciences and received the National 
Medal of Science. After leaving RU, 
Porter established laboratories of 
cell biology at Harvard University, 
the University of Colorado and the 
University of Maryland. He was a 
professor emeritus at the University 
of Pennsylvania when he died. 
NAN CY DICKERSON 
WHITEHEAD 
RU Council member Nancy 
Dickerson Whitehead died at age 70 
on Oct. 18, 1997, of stroke compli­
cations at New York Hospital. The 
wife of RU Trustee John Whitehead, 
she also served on the boards of 
Covenant House, the Hospital for 
Special Surgery and the New York 
Public Library and was a member of 
the Central Park Conservancy. 
For continually updated information 
about RU, visit our web page: 
http://www. rockefeller.edul. 
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A ball-and-stick model of a potassium ion 
channel from the bacterium Streptomyces 
lividans shows a potassium ion (red sphere) 
inside the pore. The protein is comprised of 
four identical subunits that join together like 
the staves of a barrel around the central pore. 
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